ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 840,26
1,18%
DAX
19 884,75
-0,57%
Brent Oil
72,72
0,00%
Bitcoin
97 522,16
-0,25%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Aileron Therapeutics Inc (ALRN) Cours

Aileron Therapeutics Inc

Aileron Therapeutics Inc (ALRN)

NASDAQ
1,75
-0,01
(-0,57%)
Fermé 21 Décembre 10:00PM
Retardé de 15 minutes
1,77
0,02
(1,14%)
Après les heures de négociation: 1:59AM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
1,75
Prix Achat
1,01
Prix Vente
2,70
Volume échangé
71 500
1,70 Fourchette du Jour 1,88
1,61 Plage de 52 semaines 7,42
Cap du marché
37,915M
Clôture Veille
1,76
Ouverture
1,75
Dernière Transaction
12510
@
1.75
Dernière heure de transaction
Volume financier
US$ 128 743
VWAP
1,8006
Volume moyen (3 m)
76 861
Actions en circulation
21 665 941
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-2,44
Bénéfice par action (BPA)
-0,73
Chiffre d'affairess
-
Bénéfice net
-15,73M

À propos de Aileron Therapeutics Inc

Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in pat... Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.aileronrx.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Aileron Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ALRN. Le dernier cours de clôture d'Aileron Therapeutics était de US$1,76. Au cours de la dernière année, les actions de Aileron Therapeutics ont été négociées dans une fourchette de prix de US$ 1,61 à US$ 7,42.

Aileron Therapeutics compte actuellement 21 665 941 actions en circulation. La capitalisation boursière d'Aileron Therapeutics est de US$38,13 million. Aileron Therapeutics a un ratio cours/bénéfice (ratio PE) de -2.44.

ALRN Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

09 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

06 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

06 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

06 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 Décembre 2024
Edgar (US Regulatory)

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire AUSTIN, Texas, Nov. 14, 2024 Announced promising safety and positive biomarker data...

14 Novembre 2024
PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 Novembre 2024
Edgar (US Regulatory)

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) PR Newswire WALTHAM, Mass., Nov. 13, 2024...

13 Novembre 2024
PR Newswire (US)

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma PR Newswire AUSTIN, Texas and NEW YORK, Oct. 31, 2024...

31 Octobre 2024
PR Newswire (US)

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium...

12 Octobre 2024
PR Newswire (US)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.33-15.86538461542.082.381.751266912.08819831CS
4-0.835-32.30174081242.5852.961.75892082.23354599CS
12-1.9-52.05479452053.654.41.75768613.06939535CS
26-1.31-42.81045751633.064.41.61788952.95474305CS
52-1.54-46.80851063833.297.421.61751983.65035013CS
156-8.832-83.462483462510.582151.012244195.58280845CS
260-9.424-84.33864327911.17449.41.0159407823.26944891CS

ALRN - Frequently Asked Questions (FAQ)

What is the current Aileron Therapeutics share price?
The current share price of Aileron Therapeutics is US$ 1,75
How many Aileron Therapeutics shares are in issue?
Aileron Therapeutics has 21 665 941 shares in issue
What is the market cap of Aileron Therapeutics?
The market capitalisation of Aileron Therapeutics is USD 38,13M
What is the 1 year trading range for Aileron Therapeutics share price?
Aileron Therapeutics has traded in the range of US$ 1,61 to US$ 7,42 during the past year
What is the PE ratio of Aileron Therapeutics?
The price to earnings ratio of Aileron Therapeutics is -2,44
What is the reporting currency for Aileron Therapeutics?
Aileron Therapeutics reports financial results in USD
What is the latest annual profit for Aileron Therapeutics?
The latest annual profit of Aileron Therapeutics is USD -15,73M
What is the registered address of Aileron Therapeutics?
The registered address for Aileron Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Aileron Therapeutics website address?
The website address for Aileron Therapeutics is www.aileronrx.com
Which industry sector does Aileron Therapeutics operate in?
Aileron Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
121,03M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
78,06M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
34M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,94k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
121,95M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,91M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,75M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,94M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
9,27M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
6,25M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,32M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
305,1M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
292,16M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
287,21M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
277,63M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
ALRN
Aileron Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés